Introduction {#s1}
============

Liver dysfunction and cirrhosis affect vasculature in several organ systems, resulting in impairment of organ function that leads to increased morbidity and mortality.[@pone.0094550-Zhang1], [@pone.0094550-Machicao1] Hepatopulmonary syndrome (HPS) is a pulmonary vascular disorder associated with liver cirrhosis and is seen in 5--32% of cirrhotic patients in the setting of pulmonary microvascular dilatation-induced defects in arterial oxygenation.[@pone.0094550-Zhang1], [@pone.0094550-Machicao1] Although HPS occurs more frequently in patients with severe liver disease, patients with severe hepatic dysfunction do not always have HPS. This syndrome can also be seen in children with biliary atresia, and the same disease pattern is seen in the non-cirrhosis setting in congenital heart disease patients with a post-operative status of bidirectional cavopulmonary shunt that excludes hepatic venous return through the pulmonary vasculature.[@pone.0094550-Sari1]--[@pone.0094550-Kochar1] Experimental rat models of HPS have enabled researchers to investigate the pathogenesis of this disease. Fallon et al. demonstrated that endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) in the lungs play an important role in HPS pathogenesis.[@pone.0094550-Kochar1]--[@pone.0094550-Luo1] Fallon et al. also reported that angiogenesis plays a role in the pathophysiology of HPS and explained the mechanisms underlying the activation of vascular endothelial growth factor A (VEGF-A), which is produced by inflammatory cells such as intravascular monocytes and induces angiogenesis.[@pone.0094550-Zhang2]

Establishment of a mouse model of HPS would help obtain greater insights into the genetic basis of the disease. Although some results have been reported for murine models of hepatic disease, mortality rates in mice are higher than those in rats, and limited data are available on lung pathology after common bile duct ligation (CBDL) in mice.[@pone.0094550-Beierle1]--[@pone.0094550-Alaish1] Our objectives were to establish a mouse model of lung injury by using CBDL and investigate its pulmonary pathogenesis for application in future therapeutic approaches.

Materials and Methods {#s2}
=====================

Animal model {#s2a}
------------

All animals were treated in accordance with standards of the Ehime University Animal Care Committee using approved animal protocols including animal ethics (Permit Number: 05R02-2). The Ehime University Animal Care Committee approved our animal protocols including animal ethics. All animals were treated in accordance with standards of the committee using the approved animal protocols. Eight-week-old Balb/c mice (n = 112) were obtained from Clea Japan Inc. (Tokyo) and were housed under barrier conditions. A standard sterilized laboratory diet and water were available ad libitum. All surgical procedures were performed utilizing clean techniques. All animals were anesthetized with ketamine (0.1 mg/g) and xylazine (0.01 mg/g) administered by intraperitoneal injection. After induction of anesthesia, a median abdominal incision was made and the common bile duct was identified. The duct was dissected carefully under a microscope and doubly ligated with 7--0 Prolene (Ethicon, Somerville, NJ) and transected. In the sham operation (control) group, the duct was dissected without CBDL. The abdominal incision was closed in two layers. After abdominal closure, 1.0 ml of 0.9% saline was injected subcutaneously into each mouse, and the mice were kept warm until recovery was confirmed. We continued to inject 1.0 ml of 0.9% saline subcutaneously every 2 d for 6 d; this procedure led to improved survival rates after surgery.

Mice were sacrificed between 1 and 4 weeks after surgery. Mice were anesthetized with ketamine (0.1 mg/g) and xylazine (0.01 mg/g). After we confirmed that mice were well sedated, they were given 50 µl of heparin (50 mg/ml) subcutaneously.[@pone.0094550-Miniati1] The trachea was surgically exposed and cannulated with a 20G Terumo Surflo Catheter (Terumo Corporation, Tokyo, Japan). Right cardiac ventricles were perfused with cold PBS (10 ml) under physiological pressure with an exit through the severed right atrium. The lungs were inflated and fixed at 23 cm pressure with 4% paraformaldehyde in PBS. The lungs, liver, heart, and spleen were carefully harvested with dissection of excess surrounding tissues.

A method for intrapulmonary shunt-fraction analysis in mice was established by Miniati et al.[@pone.0094550-Miniati1] Briefly, fluorescent microspheres (1.25×10^5^; diameter, 10 µm) (Molecular Probes, Eugene, OR) in PBS were injected into the inferior vena cava and all blood was aspirated from the transected right carotid artery. Aspirated microspheres were then counted manually under a fluorescence microscope (Olympus, Tokyo, Japan).

Immunohistochemistry and immunofluorescence {#s2b}
-------------------------------------------

In brief, deparaffinization and standard antigen retrieval by microwave irradiation were performed on 8-µm sections of 4% paraformaldehyde paraffin-fixed tissues. The sections were then blocked with 3% bovine serum albumin and incubated with primary antibodies against CD31 (BD Biosciences, San Diego, CA), von Willebrand factor (vWF; Chemicon International, Temecula, CA), eNOS, iNOS (BD Biosciences, San Diego, CA), Ly6G, CD68, F4/80, MMP-8, MMP-9, TIMP-1, and TIMP-4 (Abcam, Cambridge, MA). Next, secondary antibodies were applied and the samples were incubated. Sections were developed with 3,3′-diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, MO) and counter-stained with hematoxylin.

Sections were immunostained using antibodies to vWF (Chemicon International, Temecula, CA) and tumor necrosis factor alpha (TNF-α; R&D Systems, Minneapolis, MN), and Alexa Fluor anti-mouse IgG for secondary fluorescent antibodies (Molecular Probes, Eugene, OR). For nuclear staining, mounting medium with DAPI (Vector Laboratories, Burlingame, CA) was used. Pictures were taken using a fluorescence microscope (Olympus, Tokyo, Japan).

Microvascular density and quantitation were assessed as previously described by Zhang et al.[@pone.0094550-Zhang2], [@pone.0094550-Kato1] This analysis was performed in a blinded manner. Dissected lung sections that were immunostained for CD31 and vWF were used (n = 5), and pulmonary vessels with a diameter of \>100 µm were excluded from the analysis. Positive-stained cells were counted at five representative locations under high magnification (40×) using ImageJ software (National Institutes of Health) and results were averaged.

Assembly of CD31-positive cells/magnetic beads complex {#s2c}
------------------------------------------------------

Homogenized whole lungs were treated using a solution of type-1 collagenase (400 U/ml) (Worthington, Lakewood, NJ). CD31-positive cells, including pulmonary vascular endothelial cells, were collected with magnetic beads (Dynabeads; Life Technologies, Grand Island, NY) coated with anti-CD31 antibodies (BD Biosciences, San Diego, CA) as follows.[@pone.0094550-Dong1] The cellular digest was filtered through a sterile 40-µm mesh and washed three times in 10% FBS-DMEM (Wako Pure Chemical Industries, Osaka, Japan). One milliliter of the cell suspension was placed in a tube with the magnetic beads/CD31-antibody complex and rotated for 20 min at 4°C. The bead-bound cells were then washed five times with 10% FBS-DMEM and the isolated cells were used in the following procedures.

Real-time quantitative reverse transcriptional polymerase chain reaction (qRT-PCR) {#s2d}
----------------------------------------------------------------------------------

Whole pulmonary cells and CD31-positive cells were selected as described above. Total RNA was extracted from each cell in the CBDL and sham mouse groups using Isogen II (Nippon Gene, Toyama, Japan). The RNA samples were then treated with an RNase-free DNase (Ambion, Carlsbad, CA) to remove genomic DNA contaminants. Messenger RNA was quantified using SYBR Green PCR master mix (Roche, Branford, CT) with an ABI Prism 7300 Fast Real-Time PCR system. The mRNA expression levels of endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), endothelin type A receptor (ET-A), endothelin type B receptor (ET-B), kinase insert domain receptor (KDR), CC chemokine receptor type 1 (CCR1), chemokine CXC motif ligand 3 (CXCL3), CXC chemokine receptor 2 (CXCR2), chemokine CC motif ligand 9 (CCL9), matrix metallopeptidase 9 (MMP-9), interleukin-1 beta (IL-1b), and TNF-α were normalized to the levels of of β-actin. The primer sequences used for the amplification are shown in [Table 1](#pone-0094550-t001){ref-type="table"}. The experiments were performed in triplicate and independently repeated a minimum of three times.
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###### Primer sequences for quantitative RT-PCR.

![](pone.0094550.t001){#pone-0094550-t001-1}

  Target gene               Primer sequence 5\'-3\'
  ------------- --------- ---------------------------
  ET-1           forward     GTCAACACTCCCGACCACGTT
                 reverse    CTGGTTTGTCTTAGGTGTTCCTC
  eNOS           forward      CTGTGGTCTGGTGCTGGTC
                 reverse     TGGGCAACTTGAAGAGTGTG
  ET-A           forward     ACCACAGTCCATGCCATCAC
                 reverse    TCAACATCTCACAAGTCATGAG
  ET-B           forward     TTGGAGCTGAGATGTGTAAGC
                 reverse     CAGTGAAGCCATGTTGATACC
  KDR            forward    GGGATGG TCCTTGCATCAGAA
                 reverse    ACTGGTAGCCACTGGTCTGGTTG
  CCR1           forward    TTAGCTTCCATGCCTGCCTTATA
                 reverse     TCCACTGCTTCAGGCTCTTGT
  CXCL3          forward   GGAGCACCAACTGACAGGAGAGAA
                 reverse    ACCACCCTGCAGGAAGTGTCAA
  CXCR2          forward   GCTCTGACTACCACCCAACCTTGA
                 reverse   AGAAGAGCAGCTGTGACCTGCTGT
  CCL9           forward      CCAGTGGTGGGTGTACCAG
                 reverse      CTCCGATCACTGGGGTTG
  MMP9           forward   CGAACTTCGACACTGACAAGAAGT
                 reverse     GCACGCTGGAATGATCTAAGC
  IL-1b          forward   CAACCAACAAGTGATATTCTCCATG
                 reverse     GATCCACACTCTCCAGCTGCA
  TNF-α          forward      CTGTAGCCCACGTCGTAGC
                 reverse      TTGAGATCCATGCCGTTG
  β-actin        forward   CGGTTCCGATGCCCTGAGGCTCTT
                 reverse   CGTCACACTTCATGATGGAATTGA

Western blot analysis {#s2e}
---------------------

CD31-positive cells were isolated as described above and lysed in RIPA buffer (50 mM Tris-HCl containing 0.15 m NaCl, 0.1% SDS, 1% sodium cholate, 1% Nonidet P-40, 1 mm EDTA, and 0.5 mm phenylmethylsulfonyl fluoride, pH 7.4). Proteins from lung tissues were also extracted with RIPA buffer. Equal concentrations of protein from pulmonary CD31-positive cells and whole lungs were fractionated on sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immun-Blot PVDF Membranes (Bio-Rad Laboratories, Hercules, CA). Samples were incubated with primary antibodies against MMP-9, F4/80, CD31, eNOS, induced nitric oxide synthase (iNOS), and β-actin (BD Biosciences, San Diego, CA). The proteins were detected using an ECL Prime Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK) and imaged on an LAS-4000 luminescent image analyzer (Fujifilm Life Science USA, Stamford, CT).

Microarray analysis {#s2f}
-------------------

CD31-positive cells were assembled from three mice in each group. Total RNA was extracted from pulmonary CD31-positive cells and whole pulmonary cells with Isogen II and collected as one sample in each group. We used 500 ng of total RNA to generate double-stranded cDNA. The cDNA was transcribed with DIG-labeled nucleotides (Roche Diagnostics, Basel, Switzerland), fragmented, and hybridized to a Gene Chip Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA) according to the manufacturer\'s instructions. These results were analyzed using the Gene Spring GX 12.1 (Agilent Technologies, Santa Clara, CA) and Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Redwood, CA) software. Functional analysis by IPA identified the biological functions that were most significant to the data set. Fischer\'s exact test was used to calculate a p-value indicating the probability that each biological function assigned to that data set was due to chance alone. The microarray data are deposited in Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.-gov/geo>, Accession number: GSE50088) according to Minimum Information About Microarray Experiment (MIAME) guidelines.

Protein array analysis of serum {#s2g}
-------------------------------

Serum from CBDL and sham operated mice was prepared and subjected to mouse angiogenesis array (R&D Systems ARY015, Minneapolis, MN) analysis according to the manufacturer\'s instructions.

Flow cytometry {#s2h}
--------------

Two weeks and 3 weeks after CBDL, bronchoalveolar lavage (BAL) fluid was collected from CBDL and sham operated mice to analyze the neutrophil and macrophage populations. To obtain BAL fluid, the trachea was cannulated with a 20 G angiocatheter and the lungs were lavaged five times with 1 ml of 1%FCS in PBS. The fluid was collected into one FACS tube and centrifuged at 500×g for 5 min at 4°C. The cell pellet was washed in FACS buffer, stained with CD11b, Ly6G, and F4/80 antibodies (BD Biosciences, San Diego, CA), and incubated on ice for 30 minutes. After cells were washed in FACS buffer, they were resuspended in 500 µl of FACS buffer and analyzed with FACS Calibur flowcytometer (Becton Dickinson, San Jose, CA).

Statistical analysis {#s2i}
--------------------

All measurement values in this study are expressed as means ± SE. All statistical analyses were performed with JMP 8.0 and analyzed using, where appropriate, either paired t test or Wilcoxon signed rank test. All tests were two sided. Results with p-values \<0.05 were considered statistically significant.

Results {#s3}
=======

The frequency of mortality was 82.2%, 59.2%, and 34.2% at 1, 2, and 3 weeks, respectively, after CBDL ([Fig. 1A](#pone-0094550-g001){ref-type="fig"}). No mortality was observed in the sham group. Significant weight loss occurred beginning at 2 weeks after surgery ([Table 2](#pone-0094550-t002){ref-type="table"}), and appetite loss and low activity were observed prior to death. No bile leakage was observed at autopsy in the abdominal cavity of mice that died before sacrifice. To confirm the level of liver damage resulting from CBDL surgery, serum levels of liver-function markers were measured (n = 5); all of these markers were significantly elevated from 1 week after CBDL ([Table 2](#pone-0094550-t002){ref-type="table"}). The development of ascites, a parameter of liver dysfunction,[@pone.0094550-Alaish1] was observed from 1 week after surgery. To assess lung injury after surgery, arterial blood was drained from the right carotid artery for blood gas analysis. Significantly lower PaO~2~ was found in the CBDL group at 2 and 3 weeks after surgery (70.0%±2.87% and 68.4%±1.3% respectively) compared with the sham group (87.8%±1.6%) (n = 6). To confirm and compare our results with a well-established experimental hepatopulmonary syndrome model (a rat cirrhotic model of pulmonary microcirculation),[@pone.0094550-Zhang2] we applied the intrapulmonary shunt fraction calculation to our model. The resulting value for the sham group was 2.6%±1.3%. For the CBDL group, the resulting values were 4.1%±0.9% at 2 weeks after CBDL; and 4.9%±2.0% at 3 weeks after CBDL. Differences between sham and CBDL mice were not significant (P = 0.4 at 2 weeks, P = 0.3 at 3 weeks, n = 7). Histologic changes in hematoxylin-eosin staining and pulmonary vascular proliferation in immunohistochemical analysis of the lungs are shown in [Figures 1B](#pone-0094550-g001){ref-type="fig"} and [2A](#pone-0094550-g002){ref-type="fig"}. These changes were consistent with findings of a murine CBDL model in which pulmonary angiogenic processes were confirmed by immunostaining imagery.[@pone.0094550-VanSteenkiste1]

![Survival curves and histological changes in common bile duct ligated (CBDL) mice and sham operated mice.\
(A) Kaplan-Meier survival curve in common bile duct ligated (CBDL) mice (n = 44) and sham operated (control) mice (n = 41). (B) HE-stained lung sections of sham and CBDL mice: (a) sham; (b) 1 week after CBDL; (c) 2 weeks after CBDL; (d) 3 weeks after CBDL (×20). Scale bar  = 100 µm.](pone.0094550.g001){#pone-0094550-g001}

![Immunohistochemical analysis of lung tissues in common bile duct ligated (CBDL) and sham-operated (control) mice.\
(A) Immunohistochemistry of von Willebrand factor (vWF)-stained lung section of sham and CBDL mice: (a) sham; (b) 3 weeks after CBDL. Scale bar  = 100 µm. (B) Graphical summary of lung microvessel counts by immunohistochemical analysis using CD31 and vWF antibodies in mice at 1--3 weeks after CBDL and in sham operated mice. \*P\<0.05 (CBDL vs. sham).](pone.0094550.g002){#pone-0094550-g002}

10.1371/journal.pone.0094550.t002

###### Laboratory data after common bile duct ligation in mice.

![](pone.0094550.t002){#pone-0094550-t002-2}

                               sham                   CBDL, week   
  ------------------------- ----------- ------------ ------------- -------------
  AST, IU/l                   64±5.0      528±72\*     651±99\*      647±106\*
  ALT, IU/l                   30±2.0      520±46\*     492±31\*      618±107\*
  T. Bil, mg/dl               0.6±0.1     12±1.3\*     18±2.6\*      19±2.6\*
  ALP                         315±35     1485±243\*   2764±281\*    2709±386\*
  Liver weight, g/10 g BW    0.05±0.01   0.06±0.01    0.09±0.01\*   0.09±0.01\*

Values given are means ± SE.

CBDL, common bile duct ligation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T. Bil, total bilirubin; ALP, alkaline phosphatase; BW, body weight. \*p\<0.05 vs. sham.

To investigate angiogenesis in the lung after CBDL by using methods consistent with an established rat model, we performed lung microvessel counts in which we quantified increases in microvessels at 2 and 3 weeks after CBDL in comparison with the sham group ([Fig. 2A and B](#pone-0094550-g002){ref-type="fig"}).[@pone.0094550-Zhang2] A significant increase in average lung microvessel count was revealed by both CD31 and vWF staining 2 weeks after CBDL, relative to the results for the sham group. Immunostaining of lungs using eNOS and iNOS antibodies, which were reported to be highly expressed after CBDL in a rat model,[@pone.0094550-Fallon1] revealed no significant differences in eNOS and iNOS expression between the CBDL and sham groups (data not shown). Elevated ET-1, ET-A, ET-B, KDR, and eNOS mRNA expression levels have also been reported after CBDL in rats.[@pone.0094550-Fallon1]--[@pone.0094550-Luo1], [@pone.0094550-Tang1] However, our qRT-PCR analyses revealed no significant differences in mRNA expression between the CBDL and sham groups (data not shown). We thus hypothesized that lung pathogenesis in this mouse CBDL model could be different from that in the other models, and we proceeded to apply global analysis of the gene expression profile associated with this lung pathogenesis using a microarray technique.

Identification of genes in mouse CD31-positive pulmonary cells by microarray analysis {#s3a}
-------------------------------------------------------------------------------------

Based on our finding that proliferation of CD31-positive pulmonary vascular endothelial cells was more extensive after 2 weeks, we assumed that analysis of genes related to CD31-positive cells would be the key to investigating pulmonary pathogenesis after CBDL. CD31-positive pulmonary cells were selectively collected as described in the Methods, and the purity of the cell fractions was confirmed by qRT-PCR and western blot analyses.

We determined the global gene expression profiles of CD31-positive pulmonary cells in mice 2 and 3 weeks after CBDL, compared to those of sham mice, and found 79 genes that were commonly up-regulated by more than 2-fold in mice that had undergone CBDL ([Table 3](#pone-0094550-t003){ref-type="table"}). This information was used to visualize the network of gene expression patterns, and 34 genes were identified as being connected directly or indirectly to TNF-α, located at the center of the network ([Fig. 3](#pone-0094550-g003){ref-type="fig"}). To confirm the localization of TNF-α, immunofluorescence analysis was used ([Fig 4](#pone-0094550-g004){ref-type="fig"}). The results indicated that TNF-α was highly expressed in pulmonary vascular endothelial cells in the CBDL mice, when compared with the sham operated mice.

![Relevance network of gene signaling pathways identified by Ingenuity Pathway Analysis.\
Arrow charts represent all expression values (fold changes). Color-coded gene symbols: red represents up-regulation, green represents down-regulation. Tumor necrosis factor-alpha (TNF-α) plays a central role in pulmonary pathogenesis in common bile duct ligated mice.](pone.0094550.g003){#pone-0094550-g003}

![Immunofluorescent localization of von Willebrand factor (vWF) and tumor necrosis factor alpha (TNF-α).\
Representative images of lung tissues isolated 3 weeks after the CBDL or sham procedures showing vWF (red), TNF-α (green), and DAPI, nuclear staining marker (blue). (a--c) Staining at 3 weeks after the CBDL and (d--f) sham procedures. TNF-α was more highly expressed in pulmonary endothelial vascular cells at 3 weeks after CBDL than those of the sham operated group (original magnification, ×20).](pone.0094550.g004){#pone-0094550-g004}

10.1371/journal.pone.0094550.t003

###### Genes up- or down-regulated \>2.0 fold in pulmonary cells of mice at 2 and 3 weeks after CBDL, assembled by a magnetic bead/CD31-antibody complex, in comparison with levels in sham operated mice, as determined by the Gene Chip Mouse Gene 1.0 ST Array.

![](pone.0094550.t003){#pone-0094550-t003-3}

  Gene ID             Symbol                                         Gene Name Fold change                                       2w       3w
  --------------- --------------- ------------------------------------------------------------------------------------------- -------- --------
  17394                MMP8                           matrix metallopeptidase 8 (neutrophil collagenase)                       18.597   20.121
  74145                F13A1                                coagulation factor XIII, A1 polypeptide                            12.429   7.512
  20201               S100A8                                    S100 calcium binding protein A8                                11.960   13.878
  21926                 TNF                                          tumor necrosis factor                                     7.439    2.874
  56619               CLEC4E                                C-type lectin domain family 4, member E                            7.318    3.959
  12475                CD14                                              CD14 molecule                                         7.262    4.187
  13003                VCAN                                                versican                                            7.093    3.964
  100034251           Gm11428                                        predicted gene 11428                                      7.012    9.548
  104183\|12655    Chi3l3/Chi3l4                                      chitinase 3-like 3                                       6.984    3.645
  20288                MSR1                                     macrophage scavenger receptor 1                                6.929    4.557
  14058                 F10                                          coagulation factor X                                      6.638    3.471
  12772                CCR2                                    chemokine (C-C motif) receptor 2                                6.389    4.536
  20202               S100A9                                    S100 calcium binding protein A9                                6.283    7.824
  58217                TREM1                           triggering receptor expressed on myeloid cells 1                         5.96    5.005
  216799               NLRP3                                 NLR family, pyrin domain containing 3                              5.68    3.363
  20310                CXCL3                                   chemokine (C-X-C motif) ligand 3                                5.531    3.265
  20716              SERPINA3         serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3      4.557    5.632
  12768                CCR1                                    chemokine (C-C motif) receptor 1                                4.501    4.698
  12489                Cd33                                              CD33 antigen                                          4.368    4.975
  23845               CLEC5A                                C-type lectin domain family 5, member A                            4.148    4.047
  12765                CXCR2                                  chemokine (C-X-C motif) receptor 2                               4.125    5.535
  100038947           Sirpb1a                                  signal-regulatory protein beta 1A                               3.944    3.915
  83382               SIGLEC8                                sialic acid binding Ig-like lectin 8                              3.921    3.208
  12273                C5AR1                                  complement component 5a receptor 1                               3.893    2.917
  16819                LCN2                                               lipocalin 2                                          3.862    3.671
  16948                 LOX                                              lysyl oxidase                                         3.856    3.168
  12986                CSF3R                          colony stimulating factor 3 receptor (granulocyte)                       3.854    4.490
  16409                ITGAM                     integrin, alpha M (complement component 3 receptor 3 subunit)                 3.791    3.748
  17395                MMP9         matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92 kDa type IV collagenase)     3.576    4.147
  20308                CCL9                                     chemokine (C-C motif) ligand 9                                 3.551    2.835
  246256              FCGR3A                        Fc fragment of IgG, low affinity IIIa, receptor (CD16a)                    3.511    3.572
  74442                SGMS2                                       sphingomyelin synthase 2                                    3.491    2.318
  11690               ALOX5AP                           arachidonate 5-lipoxygenase-activating protein                         3.466    3.410
  170733              Klra17                       killer cell lectin-like receptor, subfamily A, member 17                    3.466    3.997
  20568                SLPI                                 secretory leukocyte peptidase inhibitor                            3.433    2.644
  18173               SLC11A1         solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1      3.212    2.344
  56221                CCL24                                    chemokine (C-C motif) ligand 24                                3.211    2.598
  27226               PLA2G7           phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)         3.21    3.009
  18733               LILRB3       leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3    3.173    3.046
  13058                CYBB                                   cytochrome b-245, beta polypeptide                               3.147    2.017
  16176                IL1B                                           interleukin 1, beta                                      3.147    2.196
  170743               TLR7                                          toll-like receptor 7                                      3.136    2.434
  278180               VSIG4                             V-set and immunoglobulin domain containing 4                          3.131    9.911
  12978                CSF1R                                 colony stimulating factor 1 receptor                              3.076    2.409
  19204                PTAFR                                  platelet-activating factor receptor                              3.049    2.502
  21810                TGFBI                            transforming growth factor, beta-induced, 68kDa                        3.004    2.992
  20556               SLFN12L                                   schlafen family member 12-like                                 3.001    2.139
  12182                BST1                                   bone marrow stromal cell antigen 1                               2.925    2.327
  15368                HMOX1                                     heme oxygenase (decycling) 1                                  2.844    2.563
  14293                FPR1                                        formyl peptide receptor 1                                   2.748    2.280
  14191                 FGR                      Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog                 2.675    2.150
  57248                Ly6a                                  lymphocyte antigen 6 complex, locus A                             2.673    3.938
  20351               SEMA4A       sema domain, immunoglobulin domain, transmembrane domain and short cytoplasmic domain, 4A   2.654    2.315
  74039                NFAM1                               NFAT activating protein with ITAM motif 1                            2.63    2.750
  16854               LGALS3                                lectin, galactoside-binding, soluble, 3                            2.627    2.037
  14131               FCGR2A                         Fc fragment of IgG, low affinity IIa, receptor (CD32)                     2.569    2.921
  12267                C3AR1                                  complement component 3a receptor 1                               2.546    3.573
  14127               FCER1G                 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide              2.529    2.279
  80885                HCAR2                                   hydroxycarboxylic acid receptor 2                               2.508    2.019
  380924               OLFM4                                            olfactomedin 4                                         2.497    2.717
  11801                CD5L                                            CD5 molecule-like                                       2.492    5.669
  12983               CSF2RB           colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)       2.444    2.262
  16658                MAFB                    v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian)                2.428    2.510
  22177               TYROBP                             TYRO protein tyrosine kinase binding protein                          2.331    2.255
  11501                ADAM8                                    ADAM metallopeptidase domain 8                                 2.327    2.410
  170744               TLR8                                          toll-like receptor 8                                      2.177    2.221
  378460               PRAM1                                 PML-RARA regulated adaptor molecule 1                             2.153    2.739
  20375                SPI1                  spleen focus forming virus (SFFV) proviral integration oncogene spi1              2.142    2.175
  14728            Gp49a/Lilrb4                  leukocyte immunoglobulin-like receptor, subfamily B, member 4                 2.007    2.302
  18507                PAX5                                              paired box 5                                          −2.068   −2.522
  14128                FCER2                       Fc fragment of IgE, low affinity II, receptor for (CD23)                    −2.08    −3.552
  12482                MS4A1                          membrane-spanning 4-domains, subfamily A, member 1                       −2.130   −2.302
  12478                CD19                                              CD19 molecule                                         −2.183   −2.643
  19695                Reg3g                                  regenerating islet-derived 3 gamma                               −2.365   −2.158
  15510                HSPD1                               heat shock 60 kDa protein 1 (chaperonin)                            −2.529   −2.360
  12517                CD72                                              CD72 molecule                                         −2.539   −2.522
  17888                MYH6                              myosin, heavy chain 6, cardiac muscle, alpha                          −3.71    −2.284
  230899               NPPA                                          natriuretic peptide A                                     −5.536   −5.525
  15505                HSPH1                                 heat shock 105 kDa/110 kDa protein 1                              −5.641   −3.651

qRT-PCR verification of microarray data {#s3b}
---------------------------------------

Seven genes associated with angiogenesis were selected for validation, and the directional fold change of each gene was confirmed using qRT-PCR analysis ([Fig. 5a-i](#pone-0094550-g005){ref-type="fig"}). Significant differences in mRNA expression of each selected gene were observed when compared with the sham operated group. Peak elevation of mRNA expression in MMP9 was observed at 4 weeks after CBDL, while that in TNF-α was observed 2 weeks after CBDL ([Fig. 5h, i](#pone-0094550-g005){ref-type="fig"}).

![Real-time PCR analysis of representative genes identified with microarray analysis (a--g) was performed in pulmonary cells assembled by magnetic beads/CD31-antibody complexes in mice 3 weeks after CBDL (CBDL) and in sham operated controls (sham).\
(a) MMP9 and (b) TNF-α. (c) CCR1, (d) CXCL3, (e) CXCR2, (f) IL-1b, and (g) CCL9. (h) and (i) were performed in whole pulmonary cells of sham and 1--4 weeks after CBDL groups. (h) MMP9 and (i) TNF-α. Values are expressed as mean ± standard error (n = 3 in each group). Y-axis abbreviations: CCL9, chemokine CC motif ligand 9; MMP9, matrix metallopeptidase 9; TNF-α, tumor necrosis factor alpha; CCR1, CC chemokine type-1 receptor; CXCL3, chemokine CXC motif ligand 3; CXCR2, CXC chemokine receptor; IL-1b, interleukin-1 beta. \*P\<0.05 (CBDL vs. sham).](pone.0094550.g005){#pone-0094550-g005}

Identification of angiogenic protein in serum by protein array analysis {#s3c}
-----------------------------------------------------------------------

To identify the proteins that were important to angiogenic processes, we analyzed mouse serum 2 and 3 weeks after CBDL in comparison to that of sham mice using protein array analysis focused on angiogenesis ([Fig. 6](#pone-0094550-g006){ref-type="fig"} and [7](#pone-0094550-g007){ref-type="fig"}, [Fig. S1](#pone.0094550.s001){ref-type="supplementary-material"}). This analysis indicated 10 up-regulated and 9 down-regulated proteins that were associated with angiogenesis ([Fig. 8](#pone-0094550-g008){ref-type="fig"}). The up-regulated expression pattern of the MMP-9 gene was also supported by protein analysis of mouse serum ([Fig. 6](#pone-0094550-g006){ref-type="fig"}, [7](#pone-0094550-g007){ref-type="fig"}). However, no significant difference was noted between the VEGF and VEGF-B protein levels in CBDL and sham mouse serum, which was different from the data obtained in rat models ([Fig. 6](#pone-0094550-g006){ref-type="fig"}, [7](#pone-0094550-g007){ref-type="fig"}).[@pone.0094550-Zhang2], [@pone.0094550-Thenappan1]

![Protein array analysis of serum from common bile duct ligated (CBDL) and sham operated mice.\
Representative proteins identified using protein array analysis in serum isolated from CBDL mice and sham operated (sham) mice.](pone.0094550.g006){#pone-0094550-g006}

![Protein array analysis of serum from common bile duct ligated (CBDL) and sham operated mice.\
Mean pixel density of representative proteins analyzed by protein array in serum isolated from CBDL and sham operated mice.](pone.0094550.g007){#pone-0094550-g007}

![Protein array analysis of serum from common bile duct ligated (CBDL) and sham operated mice.\
Representative list of up-regulated and down-regulated proteins in the serum of common bile duct ligated mice, in comparison with the levels measured in sham operated mice by using protein array analysis. CXCL16, chemokine (CXC motif ligand 16); DLL4, delta-like ligand 4; DPPIV, dipeptidyl peptidase IV; EGF, epidermal growth factor; MMP-9, matrix metallopeptidase 9; FGF, fibroblast growth factor; MCP-1, monocyte chemotactic protein-1; TIMP-1, tissue inhibitor of metalloproteinase-1; CCL2/JE/MCP-1, chemokine (CC motif) ligand 2; NOV/CCN3/IGFBP-9, nephroblastoma overexpressed; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor.](pone.0094550.g008){#pone-0094550-g008}

MMPs and TIMPs protein level and localization in impaired lungs after CBDL {#s3d}
--------------------------------------------------------------------------

The next step in investigating the mechanism of lung injury was to focus on MMP-9, which we expected to act as a key protein in angiogenesis after CBDL. Immunohistochemistry analyses revealed that MMP-9 was highly expressed in vascular endothelial cells in CBDL mice (3 weeks), contrary to the finding that MMP-9 was less expressed in lungs of the sham group ([Fig. 9a and b](#pone-0094550-g009){ref-type="fig"}). Western blot analysis of lung whole cell lysates isolated from impaired lungs also showed high expression of MMP-9 in CBDL mice compared to sham mice ([Fig. 9c](#pone-0094550-g009){ref-type="fig"}). In addition, CD31-positive pulmonary vascular cell lysates showed high expression of MMP9, 3 weeks after CBDL in comparison with the CD31-negative pulmonary cells. The CD31-positive pulmonary cells also had lower F4/80 expression than CD31-negative pulmonary cells ([Fig. 9d](#pone-0094550-g009){ref-type="fig"}). In light of the results of the microarray analysis, in which MMP8 mRNA was highly expressed in pulmonary endothelial cells, we investigated the expression of MMP8 using immunohistochemistry. We found that MMP8 was highly expressed in the lungs of the mice 3 weeks after CBDL compared with those from sham operated mice. ([Fig.9e:](#pone-0094550-g009){ref-type="fig"} lungs from mice 3 weeks after CBDL, [Fig.9f:](#pone-0094550-g009){ref-type="fig"} lungs from sham operated mice). We also examined the expression of the MMP inhibitors, TIMP-1 and TIMP-4, in lungs of CBDL and sham operated mice. A significant difference was not found among the CBDL and sham operated mice in either TIMP-1 or TIMP-4 expression in lungs. (data not shown) In addition to these data, we investigated the presence of fibrosis in lungs after CBDL using Masson trichrome staining, since we assumed that our model had the possibility of causing pulmonary fibrosis due to the high level of MMP expression. [@pone.0094550-Chakrabarti1]--[@pone.0094550-Wang1] However, the results showed that our model did not induce the development of pulmonary fibrosis at either 2 or 3 weeks after CBDL compared with sham operated mice (data not shown).

![MMP8 and MMP-9 expression in mice 3 weeks after common bile duct ligation (CBDL).\
(a) Immunoreactivity of MMP-9 (matrix metallopeptidase) is stronger than that in sham-operated mice; (b) Immunohistochemical analysis. Scale bar  = 100 µm. (c) Immunoblotting of MMP-9 in the whole pulmonary tissue of the sham and of the 2 and 3 weeks after CBDL groups revealed that MMP-9 is highly expressed in the 2 and 3 weeks after CBDL groups, compared with the expression in the sham groups. (d) Immunoblotting of F4/80, CD31, and MMP9 in the CD31-positive pulmonary cell lysates obtained 3 weeks after CBDL showed higher levels of MMP9 expression in pulmonary vascular endothelial cells compared with those of CD31-negative pulmonary cells. (e) Immunoreactivity of MMP-8 is stronger than that in sham-operated mice; (f) Immunohistochemical analysis. Scale bar  = 100 µm.](pone.0094550.g009){#pone-0094550-g009}

Neutrophils increase in the lungs of mice after CBDL {#s3e}
----------------------------------------------------

To investigate whether inflammatory cells contribute to the pulmonary pathogenesis in mice after CBDL, cells were collected from BAL fluid obtained from CBDL and sham operated mice and analyzed by flow cytometry. We found that CD11b positive and Ly6G positive cells, which are defined as neutrophils, were significantly increased 2 weeks after CBDL treatment. ([Fig.10](#pone-0094550-g010){ref-type="fig"} a and b) Moreover, immunohistochemistry showed that Ly6G was highly expressed in lungs both at 2 and 3 weeks after CBDL, when compared with the lungs from sham operated mice. We also investigated whether the number of macrophages, i.e., those identified as CD11b-positive and F4/80-positive cells using flow cytometry analysis, were increased in the BAL fluid of mice after CBDL. Surprisingly, we found no significant increase in macrophages contrary to findings from the CBDL rat model (data not shown). [@pone.0094550-Zhang2], [@pone.0094550-Thenappan1] In addition, immunohistochemistry did not show expression of either CD68 or F4/80 in the lungs of mice that had CBDL.

![CBDL increases the number of neutrophils in bonchoalveolar lavage fluid.\
Neutrophils (CD11b-positive and Ly6G-positive cells) identified by flow cytometry were increased 2 and 3 weeks after CBDL. (a) Quantitation of total neutrophils in the BAL fluid showed a significant increase 2 and 3 weeks after CBDL compared with sham operated mice. (b) Ly6G expression is higher in the lungs of mice 2 and 3 weeks after CBDL compared with sham operated mice using immunohistochemical analysis. ([Fig. 10c](#pone-0094550-g010){ref-type="fig"})](pone.0094550.g010){#pone-0094550-g010}

Discussion {#s4}
==========

Cirrhosis results in disorders such as HPS, which is characterized by hypoxemia, high cardiac output, and extrahepatic lesions, all of which increase morbidity and mortality.[@pone.0094550-Zhang1] The same pattern of lung lesions, the pathological mechanism of which has not yet been clarified, is seen in patients with bi-directional cavopulmonary shunts.[@pone.0094550-Schranz1] Models of these diseases have been established in rats,[@pone.0094550-Fallon1], [@pone.0094550-Tipps1], [@pone.0094550-Chang1] but to the best of our knowledge, only two studies have reported mouse models of pulmonary disease.[@pone.0094550-Beierle1], [@pone.0094550-Alaish1] We hypothesized that if a mouse model were established for this lung pathology, we could use a more extensive approach for resolving lung lesions by using transgenic or knockout mice. Therefore, we established a lung injury model by using CBDL, which incidentally had a higher survival rate than previous mouse models. [@pone.0094550-Beierle1], [@pone.0094550-Alaish1] Contrary to our expectation, lung pathology in our mouse model exhibited differences from that of rat models.[@pone.0094550-Fallon1], [@pone.0094550-Zhang2] The mechanisms responsible for the differences in pulmonary pathogenesis between mice and rats are unknown. In studies of humans with acute obstructive cholangitis (AOC) or other sepsis related to bile duct obstruction, the onset of multiple organ dysfunction (MOD) involving lungs is a complication associated with high morbidity and mortality.[@pone.0094550-Zhang1], [@pone.0094550-Sugiyama1] Hence, we suggest that our mouse model can be applied to pulmonary pathological analyses in the inflammatory phase, i.e., to systemic inflammatory response syndrome, acute lung injury, and MOD syndrome.[@pone.0094550-Beierle1], [@pone.0094550-GonzalezLopez1], [@pone.0094550-Keck1]

Our findings showed that TNF-α plays an important role in development of pulmonary pathology including angiogenesis not associated with release of VEGF. On the other hand, in the rat model of CBDL, TNF-α plays an important role in pulmonary angiogenesis associated with VEGF-A-mediated angiogenic pathways.[@pone.0094550-Zhang2] This phenomenon may be explained by contrasting processes related to TNF-α induction of angiogenic signaling pathways in the inflammatory phase. TNF-α is secreted by macrophages, monocytes, and endothelial cells during inflammation. Activated neutrophils work to defend against inflammation, while overstimulated neutrophils injure tissues.[@pone.0094550-Chakrabarti2], [@pone.0094550-Phillipson1] TNF-α also induces expression of proangiogenic factors and primes vascular endothelial cells for angiogenic sprouting, while simultaneously blocking VEGF-induced proliferation in vitro.[@pone.0094550-Sainson1] TNF-α has also been reported to up-regulate VEGFR-2 expression and promote angiogenesis *in vitro*.[@pone.0094550-Zhang3], [@pone.0094550-Giraudo1] Consequently, these two types of processes may help explain differences between mice and rats in angiogenic pathways after CBDL.

MMPs play an important role in the pulmonary pathogenesis of inflammatory lung diseases in human, which was reported by Kong et al.[@pone.0094550-Kong1], [@pone.0094550-Kong2] MMP-8 (neutrophil collagenase), which was elevated in both serum protein and pulmonary endothelial cells in this study, are released by activated neutrophils, and contributes to the formation and progression of acute lung injury and lung fibrosis.[@pone.0094550-Kong2], [@pone.0094550-GarciaPrieto1] This pulmonary pathogenesis was confirmed by the absence of MMP-8 in mice has an antifibrotic effect to bleomycin induced lung fibrosis.[@pone.0094550-GarciaPrieto1] MMP-9 (type IV collagenase) has the ability to degrade gelatins and basement membrane collagen.[@pone.0094550-Bendeck1] MMP-9 is known to exist in small quantities in healthy human lungs and to be produced at high levels by inflammatory cells (i.e., macrophages, polymorphonuclear neutrophils, and monocytes) in several lung diseases.[@pone.0094550-Atkinson1] For a rodent ventilator-induced lung injury model, Kim et al. reported that lungs impaired by high tidal volume had higher expression of MMP-9 than lungs ventilated by low tidal volume and related this finding to neutrophilic inflammation.[@pone.0094550-Kim1] Keck et al. reported that MMP-9 was a valid marker for predicting the development of lung damage and was required for migration of neutrophils into lung tissue in the rodent acute pancreatitis model.[@pone.0094550-Keck1], [@pone.0094550-Keck2] Johnson et al. reported that MMP-9 was required for angiogenesis in ischemic limbs and suggested that macrophages act as the source of MMP-9.[@pone.0094550-Johnson1]

In the present study, we found a high level of MMP9 production in CBDL mice serum on performing protein array analysis ([Fig. 6](#pone-0094550-g006){ref-type="fig"}). Strong gene expression and protein production of MMP9 were detected in CD31-positive cells ([Fig. 5h](#pone-0094550-g005){ref-type="fig"}). Moreover, invasive and proliferative endothelial cells were mostly observed in CBDL mice by immunohistochemical and HE staining ([Fig. 1](#pone-0094550-g001){ref-type="fig"}--[2](#pone-0094550-g002){ref-type="fig"}). Taken together, these findings suggest that MMP-9, mainly derived from endothelial cells, may play an important role in regulating angiogenesis in lung injury after CBDL. The next step will be to use MMP-9 knockout mice in analyses of treatment for cirrhosis-induced lung injury. In our model, the reason that lung fibrosis, which was assessed with Masson trichrome staining, was not strongly induced might be explained as follows; firstly, MMP-9, which is secreted from increased neutrophils during inflammation plays a role in suppression of fibrosis in the tissue.[@pone.0094550-Chakrabarti1] Secondly, unbalanced MMP and TIMP expression during the time course we used was reported to contribute to development of experimental pulmonary fibrosis: lung MMP-2 and MMP-9 m-RNA levels have peak levels and less pulmonary fibrosis is present 1 week after induction, while MMPs inhibitors, such as TIMPs, have a different peak and are present at higher levels 3 weeks after pulmonary fibrosis induction [@pone.0094550-Oggionni1], [@pone.0094550-Wang1] Lastly, the mice strain used, which was Balb/c, might have affected the development or severity of pulmonary fibrosis, as Walkin et al. described that this strain is resistant to pulmonary fibrosis, but susceptible to hepatic fibrosis. [@pone.0094550-Walkin1]

Data from our CBDL model in mice did not mimic what is observed in rats particularly in regards to HPS pathophysiology, contrary to our expectations. The TNF-α inhibitor pentoxifylline has a beneficial effect on HPS development in rats model; however, no efficient improvement of arterial oxygenation could be observed in a pilot study of pentoxifylline administration against human HPS patients. [@pone.0094550-Tanikella1] These findings suggest that HPS pathophysiology is complex and imply that a number of details regarding the mechanism of HPS are still unclear. However, we believe that our findings contribute to our understanding of HPS pathophysiology in humans and provide insights that may help in the development of efficacious therapies against this disease. [@pone.0094550-Roberts1]

In conclusion, we have shown that pulmonary pathogenesis occurs after CBDL in a mouse model and demonstrated differences between this model and other experimental animal models of hepatopulmonary syndrome. This model, which is similar to systemic inflammatory response syndrome, can be used to assess pulmonary pathology in the activated inflammation phase.
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